logo-loader
viewVerona Pharma

Verona Pharma COPD trial results carried in scientific journal

Respiratory Research carried the data from Verona’s four-week, 400-patient study first released in 2018

Verona Pharma -

Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said the results from a successful phase IIb clinical trial of its drug for chronic obstructive pulmonary disease (COPD) have been published in a peer-reviewed scientific journal.

Respiratory Research carried the data from Verona’s four-week, 400-patient study first released in 2018.

The results showed the company’s drug, ensifentrine, produced a clinically and statistically significant improvements in lung function at all doses.

Also, secondary targets were achieved, including significant progressive improvements in COPD symptoms.

The paper can be accessed here.

Quick facts: Verona Pharma

Price: 65.5 GBX

AIM:VRP
Market: AIM
Market Cap: £68.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Verona Pharma has compound with 'massive potential to impact lives of COPD...

Verona Pharma PLC (LON:VRP) chairman David Ebsworth tells Proactive London's Andrew Scott the company's made 'massive progress' in the last few years. ''When we started it was really three or four people, we didn't have a  lot of money, we had early data and over the last five years...

on 2/12/19

2 min read